|
WO1997042329A1
(en)
*
|
1996-05-04 |
1997-11-13 |
Zeneca Limited |
Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system
|
|
WO1998035988A1
(en)
*
|
1997-02-14 |
1998-08-20 |
Zeneca Limited |
Proteins
|
|
GB9709421D0
(en)
*
|
1997-05-10 |
1997-07-02 |
Zeneca Ltd |
Chemical compounds
|
|
EP1056859A1
(en)
*
|
1998-02-25 |
2000-12-06 |
The Dow Chemical Company |
High affinity humanized anti-cea monoclonal antibodies
|
|
EP1131428A2
(en)
*
|
1998-11-19 |
2001-09-12 |
Incyte Pharmaceuticals, Inc. |
Immunoglobulin superfamily proteins
|
|
AU2186900A
(en)
*
|
1998-12-21 |
2000-07-12 |
Eli Lilly And Company |
Recombinant synthesis of beta-lipotropin and other peptides
|
|
GB2371803A
(en)
*
|
1999-11-18 |
2002-08-07 |
Oxford Biomedica Ltd |
Antibodies
|
|
AU1290001A
(en)
*
|
1999-11-18 |
2001-05-30 |
Oxford Biomedica (Uk) Limited |
Antibodies
|
|
EP1283719B1
(de)
*
|
2000-04-22 |
2007-09-05 |
PharmedArtis GmbH |
Apoptotika
|
|
GB0210783D0
(en)
*
|
2002-05-10 |
2002-06-19 |
Polonelli Luciano |
Anti-microbial polypeptides
|
|
KR100604037B1
(ko)
*
|
2002-08-02 |
2006-07-24 |
주식회사유한양행 |
항체 경쇄 카파 발현벡터
|
|
US20050008618A1
(en)
*
|
2003-02-27 |
2005-01-13 |
Howard Kaufman |
Composition for delivering an agent to a target cell and uses thereof
|
|
WO2004078937A2
(en)
*
|
2003-03-04 |
2004-09-16 |
Alexion Pharmaceuticals, Inc. |
Vectors used to create hybrid constant regions
|
|
EP1631590B1
(en)
*
|
2003-04-23 |
2011-07-27 |
Medarex, Inc. |
Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
|
|
JP4982183B2
(ja)
*
|
2003-12-12 |
2012-07-25 |
ジェネンコー・インターナショナル・インク |
Ｃａｂ分子
|
|
CA2556027C
(en)
|
2004-02-12 |
2015-11-24 |
Morphotek, Inc. |
Monoclonal antibodies that specifically block biological activity of a tumor antigen
|
|
DE602005023138D1
(de)
*
|
2004-04-15 |
2010-10-07 |
Genencor Int |
Anti-cea scfv-beta-lactamase konstrukte (cab moleküle) in adept
|
|
CN101072578A
(zh)
|
2004-10-29 |
2007-11-14 |
南加州大学 |
用共刺激分子的联合癌症免疫疗法
|
|
CA2600505C
(en)
|
2005-03-10 |
2016-05-03 |
Morphotek, Inc. |
Anti-mesothelin antibodies
|
|
WO2006116592A2
(en)
|
2005-04-22 |
2006-11-02 |
Morphotek, Inc. |
Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
|
|
EP1942939B2
(en)
|
2005-09-30 |
2021-07-07 |
Medimmune Limited |
Interleukin-13 antibody composition
|
|
US8993295B2
(en)
|
2006-07-20 |
2015-03-31 |
The General Hospital Corporation |
Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
|
|
US8043830B2
(en)
*
|
2008-02-01 |
2011-10-25 |
The Regents Of The University Of California |
Biotin-ligase system for secretion of biotinylated protein
|
|
CN101607985B
(zh)
*
|
2008-12-24 |
2013-03-27 |
中国科学院生物物理研究所 |
抗人cea的单克隆抗体，包含其的组合物，及其用途
|
|
CN101704892B
(zh)
*
|
2009-12-09 |
2014-02-12 |
中国人民解放军军事医学科学院生物工程研究所 |
一种抗uPAR人源化抗体及其编码基因与应用
|
|
WO2011094259A2
(en)
|
2010-01-28 |
2011-08-04 |
Glaxo Group Limited |
Cd127 binding proteins
|
|
CN107903325B
(zh)
|
2011-05-16 |
2021-10-29 |
埃泰美德(香港)有限公司 |
多特异性fab融合蛋白及其使用方法
|
|
EP3559049B1
(en)
|
2011-10-28 |
2025-06-11 |
Teva Pharmaceuticals Australia Pty Ltd |
Polypeptide constructs and uses thereof
|
|
CN102526707B
(zh)
*
|
2012-01-13 |
2015-04-22 |
成都博发生物技术有限公司 |
共刺激因子及融合蛋白的新用途
|
|
RU2493166C1
(ru)
*
|
2012-04-09 |
2013-09-20 |
Общество с ограниченной ответственностью "Технофарма" |
Наноантитело, специфически связывающее белок сеа, способ его использования для детекции этого белка
|
|
CN102838676A
(zh)
*
|
2012-09-26 |
2012-12-26 |
李彬 |
一种癌胚抗原单抗及包含该抗体的芯片以及应用
|
|
EP2839860B1
(en)
|
2012-10-12 |
2019-05-01 |
MedImmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
WO2014140174A1
(en)
|
2013-03-13 |
2014-09-18 |
Spirogen Sàrl |
Pyrrolobenzodiazepines and conjugates thereof
|
|
ES2938708T3
(es)
|
2013-04-29 |
2023-04-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado
|
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
|
EP3193940A1
(en)
|
2014-09-10 |
2017-07-26 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
|
EA037749B1
(ru)
|
2014-10-29 |
2021-05-18 |
Тева Фармасьютикалз Острэйлиа Пти Лтд |
ВАРИАНТЫ ИНТЕРФЕРОНА 2b
|
|
AU2017233121B2
(en)
|
2016-03-15 |
2023-12-21 |
Itabmed (Hk) Limited |
Multispecific Fab fusion proteins and use thereof
|
|
WO2018014067A1
(en)
|
2016-07-19 |
2018-01-25 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-cd47 combination therapy
|
|
EP3525829A1
(en)
|
2016-10-11 |
2019-08-21 |
Medimmune Limited |
Antibody-drug conjugates with immune-mediated therapy agents
|
|
CN106749667B
(zh)
*
|
2016-12-04 |
2020-07-14 |
深圳市国创纳米抗体技术有限公司 |
一种抗癌胚抗原的纳米抗体及其应用
|
|
MX2020012418A
(es)
|
2018-05-23 |
2021-04-28 |
Adc Therapeutics Sa |
Adyuvante molecular.
|
|
CN112867735B
(zh)
|
2018-09-07 |
2025-05-09 |
埃泰美德(香港)有限公司 |
双特异性抗原结合蛋白及其用途
|
|
CA3149543A1
(en)
*
|
2019-08-27 |
2021-03-04 |
Donald M. O'rourke |
Synthetic cars to treat il13r.alpha.2 positive human and canine tumors
|
|
US20230372528A1
(en)
|
2020-10-16 |
2023-11-23 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
|
CN115850483B
(zh)
*
|
2020-10-21 |
2025-09-19 |
北京纽安博生物技术有限公司 |
抗CEACAM6单域抗体、人源化单域抗体及其Fc融合蛋白和应用
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
KR20240095442A
(ko)
|
2021-11-03 |
2024-06-25 |
항저우 디에이씨 바이오테크 씨오, 엘티디 |
항체의 특이적 접합
|